Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

Maria Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Spicka, Rik Schots, Tomasz Wrobel, Gordon Cook, Meral Beksac, Katharine S. Gries, Anupa Kudva, Brenda Tromp, Rian Van Rampelbergh, Huiling Pei, Susan Wroblewski, Robin Carson, Maria Delioukina, Darrell White

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
Original languageEnglish
Pages (from-to)1172-1177
Number of pages6
JournalJournal of Oncology Pharmacy Practice
Volume29
Issue number5
DOIs
Publication statusPublished - Jul 2023
Externally publishedYes

ASJC Scopus Subject Areas

  • Pharmacology (medical)
  • Oncology

Keywords

  • Multiple myeloma
  • daratumumab
  • intravenous
  • subcutaneous
  • transplant-ineligible

Fingerprint

Dive into the research topics of 'Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this